Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) Cost of Revenue (2016 - 2023)

Perspective Therapeutics' Cost of Revenue history spans 14 years, with the latest figure at -$4.9 million for Q4 2023.

  • For Q4 2023, Cost of Revenue changed N/A year-over-year to -$4.9 million; the TTM value through Dec 2023 reached -$2.3 million, changed N/A, while the annual FY2022 figure was $6.2 million, 153.24% up from the prior year.
  • Cost of Revenue for Q4 2023 was -$4.9 million at Perspective Therapeutics, down from $855000.0 in the prior quarter.
  • Across five years, Cost of Revenue topped out at $3.0 million in Q2 2022 and bottomed at -$4.9 million in Q4 2023.
  • The 5-year median for Cost of Revenue is $855000.0 (2023), against an average of $590052.6.
  • The largest annual shift saw Cost of Revenue plummeted 203.23% in 2021 before it surged 370.21% in 2022.
  • A 5-year view of Cost of Revenue shows it stood at $1.1 million in 2019, then tumbled by 43.47% to $619000.0 in 2020, then surged by 59.94% to $990000.0 in 2021, then fell by 19.19% to $800000.0 in 2022, then plummeted by 707.88% to -$4.9 million in 2023.
  • Per Business Quant, the three most recent readings for CATX's Cost of Revenue are -$4.9 million (Q4 2023), $855000.0 (Q3 2023), and $147000.0 (Q2 2023).